Neuropace Historical Income Statement

NPCE Stock  USD 9.70  0.70  7.78%   
Historical analysis of Neuropace income statement accounts such as Selling General Administrative of 44.6 M can show how well Neuropace performed in making a profits. Evaluating Neuropace income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Neuropace's future profits or losses.
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Neuropace latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Neuropace is a good buy for the upcoming year.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neuropace. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
For information on how to trade Neuropace Stock refer to our How to Trade Neuropace Stock guide.

About Neuropace Income Statement Analysis

Neuropace Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Neuropace shareholders. The income statement also shows Neuropace investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Neuropace Income Statement Chart

At present, Neuropace's Research Development is projected to increase significantly based on the last few years of reporting.

Interest Expense

The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.

Total Revenue

Total revenue comprises all receipts Neuropace generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Neuropace minus its cost of goods sold. It is profit before Neuropace operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Neuropace. It is also known as Neuropace overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.
Most accounts from Neuropace's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Neuropace current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neuropace. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
For information on how to trade Neuropace Stock refer to our How to Trade Neuropace Stock guide.At present, Neuropace's Research Development is projected to increase significantly based on the last few years of reporting.
 2021 2022 2023 2024 (projected)
Depreciation And Amortization296K3.0M1.6M1.6M
Interest Income448K1.6M3.1M3.2M

Neuropace income statement Correlations

0.860.17-0.920.940.790.780.94-0.81-0.78-0.770.91-0.790.830.950.73-0.780.47-0.01-0.910.86
0.860.07-0.670.880.890.880.9-0.59-0.48-0.420.8-0.440.920.880.67-0.480.590.28-0.840.95
0.170.07-0.160.13-0.2-0.240.15-0.58-0.41-0.470.54-0.37-0.050.190.46-0.410.79-0.680.250.22
-0.92-0.67-0.16-0.75-0.52-0.51-0.750.790.810.83-0.820.85-0.55-0.77-0.580.81-0.30.140.83-0.67
0.940.880.13-0.750.890.871.0-0.79-0.76-0.710.87-0.730.921.00.85-0.760.45-0.03-0.860.93
0.790.89-0.2-0.520.891.00.9-0.43-0.39-0.320.61-0.360.990.860.58-0.390.320.41-0.870.84
0.780.88-0.24-0.510.871.00.88-0.4-0.36-0.30.58-0.340.980.850.55-0.360.280.44-0.870.82
0.940.90.15-0.751.00.90.88-0.79-0.74-0.690.88-0.710.931.00.85-0.740.5-0.01-0.850.94
-0.81-0.59-0.580.79-0.79-0.43-0.4-0.790.960.95-0.940.93-0.52-0.83-0.910.96-0.570.570.54-0.76
-0.78-0.48-0.410.81-0.76-0.39-0.36-0.740.960.99-0.830.99-0.45-0.78-0.861.0-0.320.60.57-0.67
-0.77-0.42-0.470.83-0.71-0.32-0.3-0.690.950.99-0.830.99-0.39-0.74-0.80.99-0.340.630.53-0.6
0.910.80.54-0.820.870.610.580.88-0.94-0.83-0.83-0.80.710.90.86-0.830.74-0.29-0.670.87
-0.79-0.44-0.370.85-0.73-0.36-0.34-0.710.930.990.99-0.8-0.41-0.75-0.780.99-0.260.580.59-0.6
0.830.92-0.05-0.550.920.990.980.93-0.52-0.45-0.390.71-0.410.910.66-0.450.450.32-0.840.89
0.950.880.19-0.771.00.860.851.0-0.83-0.78-0.740.9-0.750.910.87-0.780.5-0.07-0.840.94
0.730.670.46-0.580.850.580.550.85-0.91-0.86-0.80.86-0.780.660.87-0.860.56-0.47-0.510.87
-0.78-0.48-0.410.81-0.76-0.39-0.36-0.740.961.00.99-0.830.99-0.45-0.78-0.86-0.320.60.57-0.67
0.470.590.79-0.30.450.320.280.5-0.57-0.32-0.340.74-0.260.450.50.56-0.32-0.17-0.150.62
-0.010.28-0.680.14-0.030.410.44-0.010.570.60.63-0.290.580.32-0.07-0.470.6-0.17-0.310.0
-0.91-0.840.250.83-0.86-0.87-0.87-0.850.540.570.53-0.670.59-0.84-0.84-0.510.57-0.15-0.31-0.77
0.860.950.22-0.670.930.840.820.94-0.76-0.67-0.60.87-0.60.890.940.87-0.670.620.0-0.77
Click cells to compare fundamentals

Neuropace Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Neuropace is a strong investment it is important to analyze Neuropace's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Neuropace's future performance. For an informed investment choice regarding Neuropace Stock, refer to the following important reports:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neuropace. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
For information on how to trade Neuropace Stock refer to our How to Trade Neuropace Stock guide.
You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neuropace. If investors know Neuropace will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neuropace listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.98)
Revenue Per Share
2.697
Quarterly Revenue Growth
0.282
Return On Assets
(0.15)
Return On Equity
(2.15)
The market value of Neuropace is measured differently than its book value, which is the value of Neuropace that is recorded on the company's balance sheet. Investors also form their own opinion of Neuropace's value that differs from its market value or its book value, called intrinsic value, which is Neuropace's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neuropace's market value can be influenced by many factors that don't directly affect Neuropace's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neuropace's value and its price as these two are different measures arrived at by different means. Investors typically determine if Neuropace is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuropace's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.